10-Q: ResMed Inc. Reports Strong Q3 2025 Results, Driven by Increased Demand and Strategic Growth Initiatives

ResMed Inc. announces an 8% increase in net revenue for the third quarter of fiscal year 2025, driven by strong performance in both Sleep and Breathing Health and Residential Care Software segments.

Summary

• ResMed Inc. reported an 8% increase in net revenue for the three months ended March 31, 2025, reaching $1.3 billion.
• The Sleep and Breathing Health segment saw an 8% increase in revenue, while the Residential Care Software segment grew by 9%.
• Gross margin improved to 59.3% compared to 57.9% in the same period last year, driven by manufacturing efficiencies and favorable product mix.
• Diluted earnings per share increased to $2.48, up from $2.04 in the prior year.
• The company invested $83.9 million in research and development, representing 6.5% of net revenues.
• Cash and cash equivalents totaled $932.7 million, with total assets at $7.6 billion and stockholders' equity at $5.5 billion as of March 31, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, revenue growth, and strategic initiatives. While there are some risks and negative impacts, the overall tone is optimistic and indicates a healthy business trajectory.

Positives

• Strong revenue growth in both Sleep and Breathing Health and Residential Care Software segments.
• Improved gross margin due to manufacturing efficiencies and favorable product mix.
• Increased diluted earnings per share.
• Continued investment in research and development to drive future innovation.
• Healthy cash position and available liquidity under the revolving credit facility.

Negatives

• Unfavorable foreign currency movements negatively impacted net revenue by approximately $12.9 million for the three months ended March 31, 2025.
• The company recorded a loss associated with its equity investments of $5.6 million for the three months ended March 31, 2025 compared to a gain of $13.9 million for the three months ended March 31, 2024.

Risks

• Global macroeconomic conditions, including inflation and supply chain disruptions, could adversely affect operations and profitability.
• Changes in healthcare regulations and reimbursement policies could impact the business.
• The company faces risks related to third-party coverage and reimbursement, as well as disruptions at the FDA and other government agencies.
• Fluctuations in foreign currency exchange rates could have an adverse effect on financial results.

Future Outlook

The company is committed to ongoing investment in research and development and product enhancements, and expects its products and solutions to provide a strong platform for future growth.

Management Comments

• During fiscal year 2024, we announced a new operating model to accelerate long-term growth.
• This change aims to increase the velocity of product development and sharpen our customer and brand focus.
• Ultimately, the goal is to accelerate profitable growth, while driving greater value and improved care throughout the outside hospital care continuum and the patient journey.

Industry Context

The company's growth is fueled by geographic expansion, research and product development efforts, acquisitions, and increasing awareness of sleep-disordered breathing and respiratory conditions as significant health concerns, aligning with the global healthcare systems' shift towards home-based and lower-cost care settings.

Comparison to Industry Standards

• ResMed's performance can be compared to industry peers such as Philips (though Philips has faced significant recalls and restructuring), Medtronic (which has a broader portfolio but competes in some respiratory segments), and smaller, specialized players like Fisher & Paykel Healthcare.
• ResMed's gross margin of 59.3% is generally competitive within the medical device industry, where margins can vary widely based on product mix and innovation.
• Companies like Intuitive Surgical often command higher margins due to their proprietary technology and robotic surgery systems, while commoditized segments may see lower margins.
• ResMed's R&D investment of 6.5% of net revenue is a standard benchmark for medical device companies focused on innovation and maintaining a competitive edge.
• Companies like Stryker and Zimmer Biomet also invest heavily in R&D to drive product development and market share.

Legal Proceedings

• The company is involved in various legal proceedings, claims, investigations, and litigation that arise in the ordinary course of business.
• On June 2, 2021, New York University ('NYU') filed a complaint for patent infringement in the United States District Court, District of Delaware against Resmed, case no. 1:21-cv-00813 (JPM).
• On January 27, 2021, the International Trade Commission ('ITC') instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively Philips) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively respondents).
• On June 16, 2022, Cleveland Medical Devices Inc. ('Cleveland Medical') filed suit for patent infringement against Resmed in the United States District Court for the District of Delaware, case no. 1:22-cv-00794.
• On March 20, 2023, ResMed Corp. filed suit in the United States District Court for the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. Patent No. 11,602,284 issued to Cleveland Medical.

Stakeholder Impact

• Shareholders will benefit from the increased earnings per share and continued dividend payments.
• Employees will benefit from the company's continued investment in research and development and strategic growth initiatives.
• Customers will benefit from the company's innovative products and solutions that improve patient outcomes and create efficiencies.
• The company's strong financial performance and commitment to innovation will benefit suppliers and creditors.

Next Steps

• The company will continue to invest in research and development and product enhancements.
• The board of directors approved a cash dividend of $0.53 per common share, to be paid on June 12, 2025.

Key Dates

Keywords

ResMed, financial results, quarterly report, sleep apnea, respiratory care, healthcare, medical devices, revenue, earnings, gross margin